» Articles » PMID: 21505561

Kinetics of Host Cell Recruitment During Dissemination of Diffuse Malignant Peritoneal Mesothelioma

Overview
Publisher Springer
Specialty Oncology
Date 2011 Apr 21
PMID 21505561
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Diffuse malignant mesothelioma is an aggressive tumor which displays a median survival of 11.2 months and a 5-year survival of less than 5% emphasizing the need for more effective treatments. This study uses an orthotopic model of malignant mesothelioma established in syngeneic, immunocompetent C57Bl/6 mice which produce malignant ascites and solid tumors that accurately replicate the histopathology of the human disease. Host stromal and immune cell accumulation within malignant ascites and solid tumors was determined using immunofluorescent labeling with confocal microscopy and fluorescence-activated cell sorting. An expression profile of cytokines and chemokines was produced using quantitative real-time PCR arrays. Tumor spheroids and solid tumors show progressive growth and infiltration with host stromal and immune cells including macrophages, endothelial cells, CD4(+) and CD8(+) lymphocytes, and a novel cell type, myeloid derived suppressor cells (MDSCs). The kinetics of host cell accumulation and inflammatory mediator expression within the tumor ascites divides tumor progression into two distinct phases. The first phase is characterized by progressive macrophage and T lymphocyte recruitment, with a cytokine profile consistent with regulatory T lymphocytes differentiation and suppression of T cell function. The second phase is characterized by decreased expression of macrophage chemotactic and T-cell regulating factors, an increase in MDSCs, and increased expression of several cytokines which stimulate differentiation of MDSCs. This cellular and expression profile suggests a mechanism by which host immune cells promote diffuse malignant mesothelioma progression.

Electronic Supplementary Material: The online version of this article (doi:10.1007/s12307-010-0048-1) contains supplementary material, which is available to authorized users.

Citing Articles

Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma.

Salaroglio I, Aviles P, Kopecka J, Merlini A, Napoli F, Righi L J Exp Clin Cancer Res. 2024; 43(1):327.

PMID: 39709435 PMC: 11662834. DOI: 10.1186/s13046-024-03253-y.


Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial.

Dietz M, Quintelier K, van Kooten J, de Boer N, Vink M, Brandt-Kerkhof A J Immunother Cancer. 2023; 11(8).

PMID: 37536940 PMC: 10401259. DOI: 10.1136/jitc-2023-007070.


Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Riganti C, Lingua M, Salaroglio I, Falcomata C, Righi L, Morena D Oncoimmunology. 2018; 7(3):e1398874.

PMID: 29399399 PMC: 5790353. DOI: 10.1080/2162402X.2017.1398874.


Mesothelioma response to carbon nanotubes is associated with an early and selective accumulation of immunosuppressive monocytic cells.

Huaux F, dUrsel de Bousies V, Parent M, Orsi M, Uwambayinema F, Devosse R Part Fibre Toxicol. 2016; 13(1):46.

PMID: 27549627 PMC: 4994252. DOI: 10.1186/s12989-016-0158-0.


The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of Mesothelium.

Benvenuto M, Mattera R, Taffera G, Giganti M, Lido P, Masuelli L Nutrients. 2016; 8(5).

PMID: 27171110 PMC: 4882688. DOI: 10.3390/nu8050275.


References
1.
Mohr S, Keith G, Galateau-Salle F, Icard P, Rihn B . Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim Biophys Acta. 2004; 1688(1):43-60. DOI: 10.1016/j.bbadis.2003.10.007. View

2.
Rusch V . Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997; 9(4):367-72. View

3.
Hodgson J, Darnton A . The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000; 44(8):565-601. View

4.
Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A . Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol. 2001; 18(5):1093-8. DOI: 10.3892/ijo.18.5.1093. View

5.
Fitzpatrick D, Peroni D, Bielefeldt-Ohmann H . The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol. 1995; 12(5):455-60. DOI: 10.1165/ajrcmb.12.5.7742009. View